Pexep CR 37.5 is a generic controlled-release formulation of paroxetine, designed to maintain consistent blood levels over 24 hours, which helps in reducing side effects while ensuring effective symptom management. As a potent selective serotonin reuptake inhibitor (SSRI), it enhances serotonergic neurotransmission, which plays a vital role in stabilizing mood, reducing anxiety, and alleviating symptoms related to various mental health disorders.

- Sleep & Mental Health > Depression, Anxiety, PTSD Pexep CR 37.5 effectively manages major depressive disorder (MDD), generalized anxiety disorder (GAD), panic disorder, and post-traumatic stress disorder (PTSD), promoting emotional balance and helping patients regulate their stress responses for improved daily functioning. > Obsessive-Compulsive Disorder (OCD) This medication is FDA-approved for treating OCD, significantly reducing obsessive thoughts and compulsive behaviors by restoring serotonin balance. > Panic Disorder Pexep CR 37.5 reduces the frequency and severity of panic attacks and is a mainstay in preventing relapses in panic disorder.

Paroxetine acts by selectively inhibiting serotonin reuptake transporters in the brain, increasing serotonin levels at neuronal synapses, which results in improved communication and relief from symptoms of depression, anxiety, and related disorders.

Adult Dosing - Depression & Major Depressive Disorder (MDD): Immediate Release (IR): Initial dose 20 mg daily; maintenance 20–50 mg, max 50 mg. Controlled Release (CR): Initial dose 25 mg daily; maintenance 25–62.5 mg, max 62.5 mg. Dose increments by 10 mg (IR) or 12.5 mg (CR) weekly are common. Treatment duration usually spans several months, with proven efficacy for up to one year. - Social Anxiety Disorder (SAD): IR: Start 20 mg daily; maintain 20–60 mg, max 60 mg. CR: Start 12.5 mg daily; maintain 12.5–37.5 mg, max 37.5 mg. Typically treated for up to 12 weeks with weekly dose adjustments. - Panic Disorder (PD): IR: Start 10 mg daily; maintain 10–40 mg, max 60 mg. CR: Start 12.5 mg daily; maintain 12.5–75 mg, max 75 mg. Treatment usually lasts up to 12 weeks, with weekly dose increases. - Premenstrual Dysphoric Disorder (PMDD): CR only, dosed 12.5–25 mg daily on continuous or cyclic schedules. Recommended for at least 3 cycles with weekly dose titration as needed. - Obsessive Compulsive Disorder (OCD): IR: Start 20 mg daily; maintenance 20–60 mg, max 60 mg. Long-term treatment with weekly dose increases of 10 mg. - Post-Traumatic Stress Disorder (PTSD) & Generalized Anxiety Disorder (GAD): IR: Start 20 mg daily; maintenance 20–50 mg, max 50 mg. Treatment duration up to 12 weeks with dose increases weekly. - Postmenopausal Symptoms: Mesylate capsules dosed 7.5 mg daily for vasomotor symptom relief only. Geriatric Dosing: - Start with lower doses (~10 mg daily) due to increased sensitivity; maintenance doses up to 40 mg/day for OCD, PTSD, SAD, GAD, PD, and depression. - Weekly dose increases recommended; avoid use for mild, transient anxiety.

Store Pexep CR 37.5 tablets in a sealed container, in a cool, dry place away from light, moisture, and excessive heat. Proper storage ensures the medication’s stability and effectiveness. Keep out of reach of children and pets to prevent accidental ingestion.

Common side effects include nausea, headache, dizziness, insomnia, dry mouth, sweating, fatigue, and sexual dysfunction. Rare but serious adverse reactions include serotonin syndrome, bleeding tendencies, and withdrawal symptoms if abruptly stopped. Close monitoring and dose adjustment based on patient tolerance is essential.